<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02741115</url>
  </required_header>
  <id_info>
    <org_study_id>PHN-Udenafil-02</org_study_id>
    <secondary_id>U01HL068270</secondary_id>
    <nct_id>NCT02741115</nct_id>
  </id_info>
  <brief_title>Fontan Udenafil Exercise Longitudinal Assessment Trial</brief_title>
  <acronym>FUEL</acronym>
  <official_title>Fontan Udenafil Exercise Longitudinal Assessment Trial (FUEL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mezzion Pharma Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mezzion Pharma Co. Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the clinical efficacy and safety of udenafil, an orally
      administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of
      adolescent subjects who have undergone the Fontan procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blinded, efficacy trial of the effects of udenafil vs.
      placebo on the background of standard therapy on maximal VO2 (ml/kg/min) from baseline to six
      months in adolescent survivors of the Fontan procedure. . The target sample size is 400
      subjects (200 per group).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Exercise Capacity</measure>
    <time_frame>Baseline to 26 Weeks</time_frame>
    <description>The change in exercise capacity (as measured by maximal VO2 at maximum exercise effort) from baseline to 26 weeks (or study completion)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Myocardial Performance Index (MPI)</measure>
    <time_frame>Baseline to 26 weeks</time_frame>
    <description>The change in the myocardial performance index (MPI) from baseline to 26 weeks determined by velocities obtained from blood pool Doppler assessment of the inflow and outflow tract of the dominant ventricle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in log-transformed reactive hyperemia index (InRH)</measure>
    <time_frame>Baseline to 26 weeks</time_frame>
    <description>The change in log-transformed reactive hyperemia index (lnRHI) from baseline to 26 weeks as measured by pulse amplitude tonometry (PAT) testing using the EndoPATÂ® device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Level of Serum serum brain-type natriuretic peptide BNP</measure>
    <time_frame>Baseline to 26 weeks</time_frame>
    <description>Change in Level of Serum serum brain-type natriuretic peptide BNP from baseline to 26 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Single Ventricle Heart Disease</condition>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Udenafil. One tablet twice daily for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo. One tablet twice daily for 26 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Udenafil</intervention_name>
    <description>Active drug</description>
    <arm_group_label>Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females with Fontan physiology who are 12 to less than 19 years of age at
             enrollment.

          2. Participant consent or parental/guardian consent and participant assent

          3. Participant fluency in primary language of country in which study is being conducted

        Exclusion Criteria:

          1. Weight &lt; 40 kg

          2. Height &lt; 132 cm.

          3. Hospitalization for acute decompensated heart failure within the last 12 months.

          4. Current intravenous inotropic drugs.

          5. Undergoing evaluation for heart transplantation or listed for transplantation.

          6. Diagnosis of active protein losing enteropathy or plastic bronchitis within the last 3
             years, or a history of liver cirrhosis.

          7. Known Fontan baffle obstruction, branch pulmonary artery stenosis, or pulmonary vein
             stenosis resulting in a mean gradient of &gt; 4 mmHg between the regions proximal and
             distal to the obstruction as measured by either catheterization or echocardiography,
             obtained prior to screening for the trial.

          8. Single lung physiology with greater than 80% flow to one lung.

          9. VO2 less than 50%

         10. Severe ventricular dysfunction assessed qualitatively by clinical echocardiography
             within six months prior to enrollment.

         11. Severe valvar regurgitation, ventricular outflow obstruction, or aortic arch
             obstruction assessed by clinical echocardiography within six months prior to
             enrollment.

         12. Significant renal (serum creatinine &gt; 2.0), hepatic (serum AST and/or ALT &gt; 3 times
             upper limit of normal), gastrointestinal or biliary disorders that could impair
             absorption, metabolism or excretion of orally administered medications, based on
             laboratory assessment six weeks prior to screening for the trial.

         13. Inability to complete exercise testing at baseline screening.

         14. History of PDE-5 inhibitor use within 3 months before study onset.

         15. History of any other medication for treatment of pulmonary hypertension within 3
             months before study onset.

         16. Known intolerance to oral udenafil.

         17. Frequent use of medications or other substances that inhibit or induce CYP3A4.

         18. Current use of alpha-blockers or nitrates.

         19. Ongoing or planned participation in another research protocol that would either
             prevent successful completion of planned study testing or invalidate its results.

         20. Noncardiac medical, psychiatric, and/or social disorder that would prevent successful
             completion of planned study testing or would invalidate its results.

         21. Cardiac care, ongoing or planned, at a non-study center that would impede study
             completion.

         22. For females: Pregnancy at the time of screening, pregnancy planned before study
             completion, or refusal to use an acceptable method of contraception for study duration
             if sexually active.

         23. Unable to abstain or limit intake of grapefruit juice during the duration of the
             trial.

         24. Refusal to provide written informed consent/assent.

         25. In the opinion of the primary care physician, the subject is likely to be
             non-compliant with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Paridon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Phildelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steve Paridon, MD</last_name>
    <phone>2155903532</phone>
    <email>paridon@email.chop.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David J Goldberg, MD</last_name>
    <phone>2674268143</phone>
    <email>goldbergda@email.chop.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phoenix Children's Hospital/Children's Heart Center at Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tabitha G Moe, MD</last_name>
      <phone>602-933-3366</phone>
      <email>TMoe@phoenixchildrens.com</email>
    </contact>
    <investigator>
      <last_name>Tabitha G Moe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arash Sabati, MD</last_name>
      <phone>323-361-4634</phone>
      <email>asabati@chla.edu</email>
    </contact>
    <investigator>
      <last_name>Arash Sabati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars/Sinai Heart Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruchira Garg, MD</last_name>
      <phone>310-423-1153</phone>
      <email>Ruchira.Garg@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Ruchira Garg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Davis, MD, PhD</last_name>
      <phone>858-966-5855</phone>
      <email>CDavis@rchsd.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Davis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael V DiMaria, MD</last_name>
      <phone>720-777-4420</phone>
      <email>Michael.DiMaria@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Michael V DiMaria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Cardiac Center/Alfred I. duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Shillingford, MD</last_name>
      <phone>302-651-6600</phone>
      <email>Amanda.Shillingford@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Amanda Shillingford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anitha John, MD, PhD</last_name>
      <phone>202-476-2728</phone>
      <email>AnJohn@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Anitha John, MD. PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins All Children's Heart Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Jacobs, MD</last_name>
      <phone>727-767-6666</phone>
      <email>JeffJacobs@msn.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Jacobs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Petit, MD</last_name>
      <phone>404-785-1796</phone>
      <email>PetitC@kidsheart.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Petit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children/Herman B. Wells Center for Pediatric Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Payne, MD</last_name>
      <phone>317-278-6239</phone>
      <email>RPayne@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Payne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Rhodes, MD</last_name>
      <phone>617-355-3491</phone>
      <email>Jonathan.Rhodes@cardio.chboston.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan Rhodes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Congenital Heart Center/C.S. Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-4204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurt R Schumacher, MD</last_name>
      <phone>734-764-5176</phone>
      <email>kurts@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Kurt R Schumacher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan B Wagner, MD</last_name>
      <phone>816-234-3000</phone>
      <phone_ext>59373</phone_ext>
      <email>jbwagner@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan B Wagner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University St. Louis/St.Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Canter, MD</last_name>
      <phone>314-454-6095</phone>
      <email>Canter@kids.wusti.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Canter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Children's Hospital and Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Yetman, MD</last_name>
      <email>ayetman@childrensomaha.org</email>
    </contact>
    <investigator>
      <last_name>Angela Yetman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Richmond, MD</last_name>
      <phone>212-305-6575</phone>
      <email>mr2306@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Marc Richmond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Hill, MD</last_name>
      <phone>919-668-8305</phone>
      <email>kevin.hill@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Hill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byran H Goldstein, MD</last_name>
      <phone>513-636-7072</phone>
      <email>bryan.goldstein@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Bryan H Goldstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hosptial</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naomi Kertesz, MD</last_name>
      <phone>614-722-0494</phone>
      <email>naomi.kertesz@natinwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Naomi Kertesz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Paridon, MD</last_name>
      <phone>215-590-3532</phone>
      <email>Paridon@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Paridon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Butts, MD</last_name>
      <phone>843-792-9146</phone>
      <email>Butts@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Ryan Butts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Frischhertz, MD</last_name>
      <phone>615-322-2318</phone>
      <email>benjamin.p.frischherz@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin Frischhertz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Penny, MD, PhD</last_name>
      <phone>832-826-1997</phone>
      <email>DjPenny@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Penny, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Hospital/Dept. of Pediatric Cardiology</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaji C Menon, MD</last_name>
      <phone>801-662-5400</phone>
      <email>Shaji.Menon@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Shaji C Menon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hosptial</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Files, MD</last_name>
      <phone>206-987-1787</phone>
      <email>Matthew.Files@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Files, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salil Grinde, MD</last_name>
      <phone>414-266-2380</phone>
      <email>SGrinde@chw.org</email>
    </contact>
    <investigator>
      <last_name>Salil Grinde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stollery Children's Hospital - University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew S Mackie, MD</last_name>
      <phone>7804078361</phone>
      <email>andrew.mackie@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Andrew S Mackie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>ON M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian McCrindle, MD</last_name>
      <phone>4168137609</phone>
      <email>brian.mccrindle@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Brian McCrindle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sejong General Hospital</name>
      <address>
        <city>Bucheon-si</city>
        <state>Gyeonggi-do</state>
        <zip>14754</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seong Ho Kim, MD, PhD</last_name>
      <phone>+821038912247</phone>
      <email>shkim24926@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Seong Ho Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Children's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gi Beom Kim, MD</last_name>
      <phone>+82220720266</phone>
      <email>ped9526@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Gi Beom Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2016</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fontan</keyword>
  <keyword>Maximal Oxygen Consumption</keyword>
  <keyword>Vascular Function</keyword>
  <keyword>EndoPAT</keyword>
  <keyword>Myocardial Performance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Udenafil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

